Zacks Investment Management decreased Ii Vi Inc (IIVI) stake by 15.77% reported in 2017Q2 SEC filing. Zacks Investment Management sold 10,381 shares as Ii Vi Inc (IIVI)’s stock declined 22.05%. The Zacks Investment Management holds 55,446 shares with $1.90 million value, down from 65,827 last quarter. Ii Vi Inc now has $2.98 billion valuation. It closed at $47.75 lastly. It is down 55.26% since November 30, 2016 and is uptrending. It has outperformed by 38.56% the S&P500.
ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company has market cap of $780.28 million. The firm develops its products using its antibody-drug conjugate technology. It currently has negative earnings. The companyÂ’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML.
Redmile Group Llc holds 2.26% of its portfolio in ImmunoGen, Inc. for 5.21 million shares. Fernwood Investment Management Llc owns 218,500 shares or 1.13% of their US portfolio. Moreover, Eam Investors Llc has 0.69% invested in the company for 582,865 shares. The Massachusetts-based Twin Focus Capital Partners Llc has invested 0.44% in the stock. Orbimed Advisors Llc, a New York-based fund reported 3.94 million shares.
Analysts await ImmunoGen, Inc. (NASDAQ:IMGN) to report earnings on February, 16. They expect $-0.13 earnings per share, up 66.67% or $0.26 from last year’s $-0.39 per share. After $-0.37 actual earnings per share reported by ImmunoGen, Inc. for the previous quarter, Wall Street now forecasts -64.86% EPS growth.
The stock increased 0.68% or $0.04 during the last trading session, reaching $5.9. About 239,103 shares traded. ImmunoGen, Inc. (IMGN) has declined 3.49% since November 30, 2016 and is downtrending. It has underperformed by 20.19% the S&P500.
Among 6 analysts covering II-VI (NASDAQ:IIVI), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. II-VI had 23 analyst reports since August 4, 2015 according to SRatingsIntel. The rating was maintained by Benchmark with “Buy” on Tuesday, January 24. The firm has “Buy” rating by Needham given on Wednesday, June 21. The rating was maintained by Benchmark with “Buy” on Tuesday, October 25. The company was maintained on Wednesday, January 25 by Needham. TheStreet downgraded the stock to “Buy” rating in Saturday, August 15 report. As per Wednesday, July 26, the company rating was downgraded by B. Riley & Co. The firm earned “Buy” rating on Friday, September 8 by Benchmark. As per Wednesday, November 1, the company rating was maintained by Craig Hallum. The firm has “Buy” rating given on Monday, November 13 by Needham. Benchmark maintained it with “Buy” rating and $4400 target in Tuesday, August 8 report.
Investors sentiment decreased to 0.95 in Q2 2017. Its down 0.19, from 1.14 in 2017Q1. It dived, as 44 investors sold IIVI shares while 60 reduced holdings. 31 funds opened positions while 68 raised stakes. 48.32 million shares or 1.34% more from 47.68 million shares in 2017Q1 were reported. Private Advisor Ltd Liability Company accumulated 10,704 shares. 119,303 are held by Aqr Management Limited Liability Corp. Shellback Ltd Partnership stated it has 16,043 shares or 0.05% of all its holdings. Blackrock accumulated 6.77M shares. Paradigm Asset Management Co Lc holds 0% of its portfolio in II-VI Incorporated (NASDAQ:IIVI) for 4,600 shares. Pillar Pacific Cap reported 17,100 shares or 0.08% of all its holdings. Rhumbline Advisers reported 131,153 shares. Parametric Portfolio Assoc Ltd Limited Liability Company holds 0.01% of its portfolio in II-VI Incorporated (NASDAQ:IIVI) for 184,405 shares. Aureus Asset Mngmt Ltd Liability Com holds 0.06% or 10,740 shares. Aperio Gp Ltd Limited Liability Company has invested 0% in II-VI Incorporated (NASDAQ:IIVI). Bessemer Group Incorporated Inc holds 0% of its portfolio in II-VI Incorporated (NASDAQ:IIVI) for 200 shares. Needham Inv Ltd Liability stated it has 170,000 shares. Bancorp Of New York Mellon Corp holds 0.01% or 963,544 shares. Thrivent Fincl For Lutherans reported 0.03% stake. Principal Fin Grp Inc invested 0.04% of its portfolio in II-VI Incorporated (NASDAQ:IIVI).
Analysts await II-VI Incorporated (NASDAQ:IIVI) to report earnings on January, 23. They expect $0.37 earnings per share, down 24.49% or $0.12 from last year’s $0.49 per share. IIVI’s profit will be $23.08 million for 32.26 P/E if the $0.37 EPS becomes a reality. After $0.32 actual earnings per share reported by II-VI Incorporated for the previous quarter, Wall Street now forecasts 15.63% EPS growth.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.